NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Dasatinib for acute lymphoblastic leukaemia

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Bristol-Myers Squibb Pharmaceuticals	Age Concern Cymru
(dasatinib)	Board of Community Health Councils in Wales
Patient/carer groups	British National Formulary
Action for Sick Children	Cancer Care Cymru
Afiya Trust	Department of Health, Social Services
 African Caribbean Leukaemia Trust 	and Public Safety for Northern Ireland
(ACLT)	Medicines and Healthcare products
Age Concern England	Regulatory Agency
Anthony Nolan Trust	National Association of Primary Care
 Association for Children with Life 	National Public Health Service for
Threatening or Terminal Conditions	Wales
(ACT)	NHS Alliance
Black Health Agency	NHS Confederation
 British Ethnic Health Awareness 	NHS Purchasing and Supply Agency
Foundation (BEHAF)	NHS Quality Improvement Scotland
Cancer Black Care	Scottish Medicines Consortium
Cancer Equality	
Cancer Voices	Comparator manufacturers
CANCERactive	Baxter Healthcare (cyclophosphamide)
Cancerbackup	Cephalon (doxirubicin)
Children with Leukaemia	Genus Pharmaceuticals (vincristine)
Chinese National Healthy Living	Hospira UK (cyclophosphamide,
Centre	dexamethasone and doxirubicin)
CLIC Sargent	Novartis Pharmaceuticals (imatinib)
 Confederation of Indian Organisations 	Pfizer (doxirubicin and
Counsel and Care	cyclophosphamide)
Equalities National Council	Schering-Plough (dexamethasone)
Gift – The Children's Transplant	
Charity	Relevant research groups
Help the Aged	Elimination of Leukaemia Fund
Leukaemia CARE	Institute of Cancer Research
Leukaemia Research Fund	Leukaemia Busters
Leukaemia Society (UK)	MRC Clinical Trials Unit
Macmillan Cancer Support	National Cancer Research Institute

National Institute for Health and Clinical Excellence

Consultation on the draft scope and matrix for the appraisal of dasatinib for acute lymphoblastic leukaemia Issue date: July 2008

Consultees	Commentators (no right to submit or
	appeal)
 Maggie's Centres Marie Curie Cancer Care Muslim Council of Great Britain Muslim Health Network National Cancer Alliance National Children's Bureau National Council for Palliative Care NCH – The Children's Charity South Asian Health Foundation Specialised Healthcare Alliance Sue Ryder Care Tenovus Cancer Information Centre Transplant Support Network UK Transplant WellChild Professional groups Association of Cancer Physicians British Association for Services to the Elderly British Committee for Standardisation in Haematology British Geriatrics Society British Psychosocial Oncology Society British Psychosocial Oncology Society British Transplantation Society Cancer Networks Pharmacists Forum Cancer Research UK Children's Cancer and Leukaemia Group National Blood Service Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians, Medical Oncology Joint Special Committee Royal College of Physicians, Medical Oncology Joint Special Committee Royal Pharmaceutical Society Royal Society of Medicine – Intellectual Disabilities Forum United Kingdom Clinical Pharmacy Association United Kingdom Oncology Nursing Society 	 Policy Research Institute on Ageing and Ethnicity Research Institute of the Care of Older People Evidence Review Group National Coordinating Centre for Health Technology Assessment West Midlands Health Technology Assessment Collaboration Associated Guideline Groups National Collaborating Centre for Cancer Associated Public Health Groups To be confirmed

National Institute for Health and Clinical Excellence

Consultation on the draft scope and matrix for the appraisal of dasatinib for acute lymphoblastic leukaemia Issue date: July 2008

Others • Department of Health Traffic and DOT	Consultees	Commentators (no right to submit or appeal)
 Trafford PCT Vale of Glamorgan LHB Welsh Assembly Government 	 Department of Health Trafford PCT Vale of Glamorgan LHB 	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient

National Institute for Health and Clinical Excellence

Consultation on the draft scope and matrix for the appraisal of dasatinib for acute lymphoblastic leukaemia Issue date: July 2008

organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

-

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.